Core Viewpoint - Wanfu Biology (300482) has recently received a medical device registration certificate from the Guangdong Provincial Drug Administration, indicating a significant regulatory milestone for the company [1] Company Summary - Wanfu Biology announced the receipt of a medical device registration certificate, which is a crucial step in the regulatory process for medical devices [1]

Core Viewpoint - The company plans to repurchase a portion of its shares using its own funds, with the repurchased shares intended for equity incentives or employee stock ownership plans [1] Group 1: Share Repurchase Details - The total amount for the share repurchase will not be less than 30 million yuan (including) and not more than 60 million yuan (including) [1] - The repurchase price will not exceed 34.66 yuan per share (including) [1] - The repurchase period will be within six months from the date the board of directors approves the final repurchase plan [1]

Core Viewpoint - Wanfu Bio has received medical device registration certificates from the Guangdong Provincial Drug Administration for several diagnostic kits, indicating a significant advancement in its product offerings in the medical diagnostics sector [1] Product Summary - The company announced the approval of the following diagnostic kits: - Fibrinogen (original) degradation product determination kit (immunoturbidimetric method) for quantitative detection of fibrinogen degradation products (FDP) in human plasma, aiding in the diagnosis of primary and secondary fibrinolysis [1] - Fibrinogen determination kit (coagulation method) for quantitative measurement of fibrinogen levels in human plasma, primarily used for diagnosing disseminated intravascular coagulation and monitoring thrombolytic therapy [1] - D-dimer determination kit (immunoturbidimetric method) for quantitative detection of D-dimer levels in human plasma, mainly used for diagnosing disseminated intravascular coagulation and monitoring thrombolytic treatment [1] - Anti-Xa determination kit (color substrate method) for quantitative measurement of the activity of unfractionated heparin (UFH) and low molecular weight heparin (LMWH) in human citrate anticoagulated plasma [1]

Core Viewpoint - Wanfu Biological announced on September 23 that its products, including fibrinogen degradation product determination kit, fibrinogen determination kit, D-dimer determination kit, and anti-Xa determination kit, have received medical device registration certificates from the Guangdong Provincial Medical Products Administration, which will positively impact the company's product variety and development [1] Product Registration - The following products received medical device registration certificates: - Fibrinogen (original) degradation product determination kit (immunoturbidimetric method) - Fibrinogen determination kit (coagulation method) - D-dimer determination kit (immunoturbidimetric method) - Anti-Xa determination kit (color substrate method) [1] Impact on Company Development - The acquisition of product registration certificates will further increase the variety of products sold by the company, contributing positively to its development [1]

Core Viewpoint - The company, Wanfu Biological (300482), announced a share repurchase plan amounting to between 30 million to 60 million yuan, aimed at implementing future equity incentives or employee stock ownership plans, with a maximum repurchase price of 34.66 yuan per share [1] Group 1 - The planned share repurchase amount is between 30 million to 60 million yuan [1] - The purpose of the repurchase is for future equity incentives or employee stock ownership plans [1] - The maximum repurchase price is set at 34.66 yuan per share [1]

Group 1 - The company, Wanfu Biological, announced a share repurchase plan with a total funding amount not less than RMB 30 million and not exceeding RMB 60 million [1] - The repurchase price range is set at a maximum of RMB 34.66 per share [1] - The repurchased shares will be used entirely for implementing equity incentives or employee stock ownership plans [1]

（记者 王晓波） 每经AI快讯，万孚生物9月23日晚间发布公告称，公司第五届第十四次董事会会议于2025年9月23日在 公司会议室以通讯的方式召开。会议审议了《关于回购公司股份方案的议案》等文件。 每经头条（nbdtoutiao）——报价太低遭严防，投标企业还得"解释清楚"，一场国家组织的大型采购， 为何引发全行业关注 ...

| 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2025-053 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 第五届董事会第十四次会议决议公告 公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 基于对公司未来发展前景的信心，为进一步健全公司长效激励机制，充分 保证公司业务持续成长，鼓励价值创造，公司在综合考虑经营情况、业务发展 前景、财务状况以及未来盈利能力的基础上，拟以自有资金回购公司股份（以 下简称"本次回购"），用于实施公司后续员工持股计划或股权激励。本次回 购价格不超过人民币 34.66 元/股（含）。该回购价格上限未超过公司董事会审 议通过回购股份决议前三十个交易日公司股票交易均价的 150%。回购金额为不 低于人民币 3,000 万元（含）且不超过人民币 6,000 万元（含），按照回购价格 测算，预计回购股份数量为 86.56 万股至 173.11 万股，占公司总股本的 0.18%- 0.37%。具体以实际回购的股份数量为准。 具体内容详见公司 ...

| 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2025-054 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 关于回购公司股份方案暨回购报告书的公告 公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： （一）本次回购基本情况 广州万孚生物技术股份有限公司（以下简称"万孚生物"或"公司"）于 2025 年 9 月 23 日召开第五届董事会第十四次会议，审议通过了《关于回购公 司股份方案的议案》，公司拟使用自有资金以集中竞价交易方式回购部分公司 股份（以下简称"本次回购"），主要内容如下： 2、回购股份的用途：本次回购的股份将全部用于实施股权激励或员工持 股计划。 3、回购股份的价格区间：不超过人民币 34.66 元/股（含）。 4、回购股份的资金总额：不低于人民币 3,000 万元（含）且不超过人民 币 6,000 万元（含）进行回购。 5、回购资金来源：公司自有资金。 6、回购的数量及占公司总股本的比例：按照回购资金总额的上下限及回 购价格上限 ...

Core Viewpoint - Wanfu Biological (300482.SZ) has received medical device registration certificates from the Guangdong Provincial Drug Administration for several diagnostic kits, indicating a significant advancement in its product offerings and potential market expansion [1] Group 1: Product Registration - The company has obtained registration for the following products: Fibrinogen (original) degradation product determination kit (immunoturbidimetric method) [1] - Fibrinogen determination kit (coagulation method) has also been registered [1] - D-dimer determination kit (immunoturbidimetric method) is among the newly registered products [1] - Anti-Xa determination kit (color substrate method) has received registration as well [1]